In particular, in this study we retrospectively analysed advanced melanomas that had directly progressed from stage IB/II AJCC (American Joint Committee on Cancer) 2017 [9], whose mutational status of BRAF, KRAS, NRAS and PIK3CA genes had already been tested. The gene discussed is KRAS; the disease is melanoma.